{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:43:41Z","timestamp":1792788221975,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Science and Technology Projects of the Second Affiliated Hospital of Nanjing University of Chinese Medicine","award":["SEZJY202504"],"award-info":[{"award-number":["SEZJY202504"]}],"id":[{"id":"https:\/\/ror.org\/04523zj19","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Priority Academic Program Development of Jiangsu Higher Education Institution","award":["PAPD"],"award-info":[{"award-number":["PAPD"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr Metab (Lond)"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a worldwide disease characterized by hepatic steatosis. \u03b3-glutamylcysteine (\u03b3-GC), a non-protein thiol peptide with nontoxic side effects, can alleviate insulin resistance (IR) and alcoholic liver disease (ALD). However, the role of \u03b3-GC in MASLD remains elusive. Herein, the aim of this study was to reveal the effects and underlying molecular mechanisms of \u03b3-GC in the progression of MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In vivo model of mice fed with high-fat diet (HFD) and in vitro model of hepatocytes treated with FFA (oleic acid\/palmitic acid\u2009=\u20092\/1) were established to examine the therapeutic effects and molecular mechanisms of \u03b3-GC in MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HFD mice develop dyslipidemia and hepatic steatosis due to obesity. Increased lipogenesis-related protein expression and aggravated fatty acid uptake are also observed in hepatocytes treated with FFA. Mechanistic studies suggest that \u03b3-GC can alleviate hepatic lipid deposition and steatosis through balancing lipid metabolism. Importantly, \u03b3-GC inhibits KLF10-regulated zDHHC7 transcription via activating AKT signaling, thereby suppressing zDHHC7-mediated CD36 palmitoylation and plasma membrane translocation. Ultimately, \u03b3-GC reduces CD36-mediated fatty acid uptake and attenuates FFA-associated lipogenic signaling, resulting in the amelioration of MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In summary, our results support \u03b3-GC as a candidate dipeptide for the treatment of MASLD, which alleviates hepatic lipid deposition and steatosis by inhibiting KLF10\/zDHHC7-mediated CD36 palmitoylation and plasma membrane translocation through activation of AKT signaling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12986-026-01173-6","type":"journal-article","created":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T03:45:00Z","timestamp":1783827900000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u03b3-GC mitigates MASLD by reducing CD36 palmitoylation and plasma membrane translocation mediated by AKT\/KLF10\/zDHHC7 axis"],"prefix":"10.1186","volume":"23","author":[{"given":"Jinyi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishuang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0532-7208","authenticated-orcid":false,"given":"Zhimin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"key":"1173_CR1","doi-asserted-by":"crossref","unstructured":"Rong L, Zou J, Ran W, Qi X, Chen Y, Cui H, Guo J. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne). 2022; 13:1087260.","DOI":"10.3389\/fendo.2022.1087260"},{"key":"1173_CR2","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/cvr\/cvad095","volume":"119","author":"C Grander","year":"2023","unstructured":"Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res. 2023;119:1787\u201398.","journal-title":"Cardiovasc Res"},{"key":"1173_CR3","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jhep.2022.03.031","volume":"77","author":"GA Baselli","year":"2022","unstructured":"Baselli GA, Jamialahmadi O, Pelusi S, Ciociola E, Malvestiti F, Saracino M, Santoro L, Cherubini A, Dongiovanni P, Maggioni M, et al. Rare ATG7 genetic variants predispose patients to severe fatty liver disease. J Hepatol. 2022;77:596\u2013606.","journal-title":"J Hepatol"},{"key":"1173_CR4","doi-asserted-by":"crossref","unstructured":"Yang J, Zhang Y, Yuan Y, Xie Z, Li L. Investigation of the Association between Air Pollution and Non-Alcoholic Fatty Liver Disease in the European Population: A Mendelian Randomization Study. Toxics. 2024; 12:228.","DOI":"10.3390\/toxics12030228"},{"key":"1173_CR5","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","volume":"80","author":"SJ Song","year":"2024","unstructured":"Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2024;80:e54\u20136.","journal-title":"J Hepatol"},{"key":"1173_CR6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00018-024-05434-6","volume":"81","author":"Z Wan","year":"2024","unstructured":"Wan Z, Liu X, Yang X, Huang Z, Chen X, Feng Q, Cao H, Deng H. MicroRNA-411-5p alleviates lipid deposition in metabolic dysfunction-associated steatotic liver disease by targeting the EIF4G2\/FOXO3 axis. Cell Mol Life Sci. 2024;81:398.","journal-title":"Cell Mol Life Sci"},{"key":"1173_CR7","doi-asserted-by":"crossref","unstructured":"Ter Horst KW, Serlie MJ. Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease. Nutrients. 2017; 9:981.","DOI":"10.3390\/nu9090981"},{"key":"1173_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/cvr\/cvaa319","volume":"118","author":"H Shu","year":"2022","unstructured":"Shu H, Peng Y, Hang W, Nie J, Zhou N, Wang DW. The role of CD36 in cardiovascular disease. Cardiovasc Res. 2022;118:115\u201329.","journal-title":"Cardiovasc Res"},{"key":"1173_CR9","doi-asserted-by":"publisher","first-page":"101428","DOI":"10.1016\/j.molmet.2021.101428","volume":"57","author":"H Zeng","year":"2022","unstructured":"Zeng H, Qin H, Liao M, Zheng E, Luo X, Xiao A, Li Y, Chen L, Wei L, Zhao L, et al. CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing. Mol Metab. 2022;57:101428.","journal-title":"Mol Metab"},{"key":"1173_CR10","doi-asserted-by":"publisher","first-page":"155914","DOI":"10.1016\/j.metabol.2024.155914","volume":"156","author":"H Zhu","year":"2024","unstructured":"Zhu H, Zhao T, Zhao S, Yang S, Jiang K, Li S, Kang Y, Yang Z, Shen J, Shen S, et al. O-GlcNAcylation promotes the progression of nonalcoholic fatty liver disease by upregulating the expression and function of CD36. Metabolism. 2024;156:155914.","journal-title":"Metabolism"},{"key":"1173_CR11","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1002\/jcp.30122","volume":"236","author":"J Jin","year":"2021","unstructured":"Jin J, Zhi X, Wang X, Meng D. Protein palmitoylation and its pathophysiological relevance. J Cell Physiol. 2021;236:3220\u201333.","journal-title":"J Cell Physiol"},{"key":"1173_CR12","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1038\/s41467-020-18565-8","volume":"11","author":"JW Hao","year":"2020","unstructured":"Hao JW, Wang J, Guo H, Zhao YY, Sun HH, Li YF, Lai XY, Zhao N, Wang X, Xie C, et al. CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated endocytosis. Nat Commun. 2020;11:4765.","journal-title":"Nat Commun"},{"key":"1173_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jhep.2018.04.006","volume":"69","author":"L Zhao","year":"2018","unstructured":"Zhao L, Zhang C, Luo X, Wang P, Zhou W, Zhong S, Xie Y, Jiang Y, Yang P, Tang R, et al. CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis. J Hepatol. 2018;69:705\u201317.","journal-title":"J Hepatol"},{"key":"1173_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/bs.vh.2022.09.002","volume":"121","author":"DA Averill-Bates","year":"2023","unstructured":"Averill-Bates DA. The antioxidant glutathione. Vitam Horm. 2023;121:109\u201341.","journal-title":"Vitam Horm"},{"key":"1173_CR15","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/jam.12363","volume":"116","author":"A Musatti","year":"2014","unstructured":"Musatti A, Devesa V, Calatayud M, V\u00e9lez D, Manzoni M, Rollini M. Glutathione-enriched baker\u2019s yeast: production, bioaccessibility and intestinal transport assays. J Appl Microbiol. 2014;116:304\u201313.","journal-title":"J Appl Microbiol"},{"key":"1173_CR16","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/COPD.S368645","volume":"17","author":"T Lei","year":"2022","unstructured":"Lei T, Lu T, Yu H, Su X, Zhang C, Zhu L, Yang K, Liu J. Efficacy of Vitamin C Supplementation on Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review and Meta-Analysis. Int J Chron Obstruct Pulmon Dis. 2022;17:2201\u201316.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1173_CR17","doi-asserted-by":"publisher","first-page":"114398","DOI":"10.1016\/j.jep.2021.114398","volume":"279","author":"Q Hu","year":"2021","unstructured":"Hu Q, Liu Z, Guo Y, Lu S, Du H, Cao Y. Antioxidant capacity of flavonoids from Folium Artemisiae Argyi and the molecular mechanism in Caenorhabditis elegans. J Ethnopharmacol. 2021;279:114398.","journal-title":"J Ethnopharmacol"},{"key":"1173_CR18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.redox.2017.01.014","volume":"11","author":"MH Zarka","year":"2017","unstructured":"Zarka MH, Bridge WJ. Oral administration of \u03b3-glutamylcysteine increases intracellular glutathione levels above homeostasis in a randomised human trial pilot study. Redox Biol. 2017;11:631\u20136.","journal-title":"Redox Biol"},{"key":"1173_CR19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00011-023-01691-6","volume":"72","author":"J Zhou","year":"2023","unstructured":"Zhou J, Yan X, Bi X, Lu S, Liu X, Yang C, Shi Y, Luo L, Yin Z. \u03b3-Glutamylcysteine rescues mice from TNBS-driven inflammatory bowel disease through regulating macrophages polarization. Inflamm Res. 2023;72:603\u201321.","journal-title":"Inflamm Res"},{"key":"1173_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.redox.2018.09.019","volume":"20","author":"Y Yang","year":"2019","unstructured":"Yang Y, Li L, Hang Q, Fang Y, Dong X, Cao P, Yin Z, Luo L. \u03b3-glutamylcysteine exhibits anti-inflammatory effects by increasing cellular glutathione level. Redox Biol. 2019;20:157\u201366.","journal-title":"Redox Biol"},{"key":"1173_CR21","doi-asserted-by":"publisher","first-page":"7560","DOI":"10.1039\/D2FO01246D","volume":"13","author":"S Lu","year":"2022","unstructured":"Lu S, Zhou J, Yang C, Zhang X, Shi Y, Liu J, Yan X, Liang J, Liu X, Luo L, et al. \u03b3-Glutamylcysteine ameliorates D-gal-induced senescence in PC12 cells and mice via activating AMPK and SIRT1. Food Funct. 2022;13:7560\u201371.","journal-title":"Food Funct"},{"key":"1173_CR22","doi-asserted-by":"publisher","first-page":"109404","DOI":"10.1016\/j.jnutbio.2023.109404","volume":"119","author":"J Zhou","year":"2023","unstructured":"Zhou J, Shi Y, Yang C, Lu S, Zhao L, Liu X, Zhou D, Luo L, Yin Z. \u03b3-glutamylcysteine alleviates insulin resistance and hepatic steatosis by regulating adenylate cyclase and IGF-1R\/IRS1\/PI3K\/Akt signaling pathways. J Nutr Biochem. 2023;119:109404.","journal-title":"J Nutr Biochem"},{"key":"1173_CR23","doi-asserted-by":"publisher","first-page":"e14318","DOI":"10.1111\/jfbc.14318","volume":"46","author":"J Liu","year":"2022","unstructured":"Liu J, Lu S, Zhang X, Zhou J, Yan X, Liu H, Liang J, Luo L, Zhou D, Yin Z. \u03b3-Glutamylcysteine alleviates ethanol-induced hepatotoxicity via suppressing oxidative stress, apoptosis, and inflammation. J Food Biochem. 2022;46:e14318.","journal-title":"J Food Biochem"},{"key":"1173_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","volume":"69","author":"T Tsuchida","year":"2018","unstructured":"Tsuchida T, Lee YA, Fujiwara N, Ybanez M, Allen B, Martins S, Fiel MI, Goossens N, Chou HI, Hoshida Y, Friedman SL. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol. 2018;69:385\u201395.","journal-title":"J Hepatol"},{"key":"1173_CR25","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321.","journal-title":"Hepatology"},{"key":"1173_CR26","doi-asserted-by":"publisher","first-page":"100086","DOI":"10.1016\/j.xpro.2020.100086","volume":"1","author":"M Charni-Natan","year":"2020","unstructured":"Charni-Natan M, Goldstein I. Protocol for Primary Mouse Hepatocyte Isolation. STAR Protoc. 2020;1:100086.","journal-title":"STAR Protoc"},{"key":"1173_CR27","doi-asserted-by":"crossref","unstructured":"Zhang M, Bai X, Du Q, Xu J, Wang D, Chen L, Dong K, Chen Z, Yang J. The Different Mechanisms of Lipid Accumulation in Hepatocytes Induced by Oleic Acid\/Palmitic Acid and High-Fat Diet. Molecules. 2023; 28:6714.","DOI":"10.3390\/molecules28186714"},{"key":"1173_CR28","doi-asserted-by":"publisher","first-page":"S627","DOI":"10.33549\/physiolres.933224","volume":"64","author":"A Moravcov\u00e1","year":"2015","unstructured":"Moravcov\u00e1 A, \u010cervinkov\u00e1 Z, Ku\u010dera O, Mezera V, Rychtrmoc D, Lotkov\u00e1 H. The effect of oleic and palmitic acid on induction of steatosis and cytotoxicity on rat hepatocytes in primary culture. Physiol Res. 2015;64:S627\u2013636.","journal-title":"Physiol Res"},{"key":"1173_CR29","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12943-024-02195-5","volume":"23","author":"Y Mo","year":"2024","unstructured":"Mo Y, Han Y, Chen Y, Fu C, Li Q, Liu Z, Xiao M, Xu B. ZDHHC20 mediated S-palmitoylation of fatty acid synthase (FASN) promotes hepatocarcinogenesis. Mol Cancer. 2024;23:274.","journal-title":"Mol Cancer"},{"key":"1173_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jfma.2019.03.014","volume":"119","author":"JF Huang","year":"2020","unstructured":"Huang JF, Tsai PC, Yeh ML, Huang CF, Huang CI, Hsieh MH, Dai CY, Yang JF, Chen SC, Yu ML, et al. Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis. J Formos Med Assoc. 2020;119:89\u201396.","journal-title":"J Formos Med Assoc"},{"key":"1173_CR31","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00535-018-1472-0","volume":"53","author":"K Enooku","year":"2018","unstructured":"Enooku K, Kondo M, Fujiwara N, Sasako T, Shibahara J, Kado A, Okushin K, Fujinaga H, Tsutsumi T, Nakagomi R, et al. Hepatic IRS1 and \u00df-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients. J Gastroenterol. 2018;53:1261\u201375.","journal-title":"J Gastroenterol"},{"key":"1173_CR32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019;92:82\u201397.","journal-title":"Metabolism"},{"key":"1173_CR33","first-page":"3439","volume":"26","author":"L Vergani","year":"2019","unstructured":"Vergani L. Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis. Curr MedChem. 2019;26:3439\u201356.","journal-title":"Curr MedChem"},{"key":"1173_CR34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.cbi.2006.11.004","volume":"165","author":"MJ G\u00f3mez-Lech\u00f3n","year":"2007","unstructured":"G\u00f3mez-Lech\u00f3n MJ, Donato MT, Mart\u00ednez-Romero A, Jim\u00e9nez N, Castell JV, O\u2019Connor JE. A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact. 2007;165:106\u201316.","journal-title":"Chem Biol Interact"},{"key":"1173_CR35","doi-asserted-by":"crossref","unstructured":"Mak KK, Zhang S, Chellian J, Mohd Z, Epemolu O, Dinkova-Kostova AT, Balijepalli MK, Pichika MR. Swietenine Alleviates Nonalcoholic Fatty Liver Disease in Diabetic Mice via Lipogenesis Inhibition and Antioxidant Mechanisms. Antioxidants (Basel). 2023; 12:595.","DOI":"10.3390\/antiox12030595"},{"key":"1173_CR36","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","volume":"11","author":"P Rada","year":"2020","unstructured":"Rada P, Gonz\u00e1lez-Rodr\u00edguez \u00c1, Garc\u00eda-Monz\u00f3n C, Valverde \u00c1M. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis. 2020;11:802.","journal-title":"Cell Death Dis"},{"key":"1173_CR37","doi-asserted-by":"crossref","unstructured":"Rana MS, Lee CJ, Banerjee A. The molecular mechanism of DHHC protein acyltransferases. Biochem Soc Trans. 2019; 47:157\u201367.","DOI":"10.1042\/BST20180429"},{"key":"1173_CR38","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/0092-8674(79)90321-0","volume":"17","author":"MF Schmidt","year":"1979","unstructured":"Schmidt MF, Schlesinger MJ. Fatty acid binding to vesicular stomatitis virus glycoprotein: a new type of post-translational modification of the viral glycoprotein. Cell. 1979;17:813\u20139.","journal-title":"Cell"},{"key":"1173_CR39","doi-asserted-by":"publisher","first-page":"41268","DOI":"10.1074\/jbc.M206573200","volume":"277","author":"S Lobo","year":"2002","unstructured":"Lobo S, Greentree WK, Linder ME, Deschenes RJ. Identification of a Ras palmitoyltransferase in Saccharomyces cerevisiae. J Biol Chem. 2002;277:41268\u201373.","journal-title":"J Biol Chem"},{"key":"1173_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1083\/jcb.200206120","volume":"159","author":"AF Roth","year":"2002","unstructured":"Roth AF, Feng Y, Chen L, Davis NG. The yeast DHHC cysteine-rich domain protein Akr1p is a palmitoyl transferase. J Cell Biol. 2002;159:23\u20138.","journal-title":"J Cell Biol"},{"key":"1173_CR41","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.celrep.2018.12.022","volume":"26","author":"J Wang","year":"2019","unstructured":"Wang J, Hao JW, Wang X, Guo H, Sun HH, Lai XY, Liu LY, Zhu M, Wang HY, Li YF, et al. DHHC4 and DHHC5 Facilitate Fatty Acid Uptake by Palmitoylating and Targeting CD36 to the Plasma Membrane. Cell Rep. 2019;26:209\u2013e221205.","journal-title":"Cell Rep"},{"key":"1173_CR42","doi-asserted-by":"publisher","first-page":"e54229","DOI":"10.15252\/embr.202154229","volume":"23","author":"S Yang","year":"2022","unstructured":"Yang S, Jia L, Xiang J, Yang G, Qiu S, Kang L, Zheng P, Liang Z, Lu Y. KLF10 promotes nonalcoholic steatohepatitis progression through transcriptional activation of zDHHC7. EMBO Rep. 2022;23:e54229.","journal-title":"EMBO Rep"},{"key":"1173_CR43","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, Congly SE, Kaplan GG, Shaheen AA. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1173_CR44","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966\u201386.","journal-title":"Hepatology"},{"key":"1173_CR45","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1038\/s41591-023-02602-2","volume":"29","author":"TJ Kendall","year":"2023","unstructured":"Kendall TJ, Jimenez-Ramos M, Turner F, Ramachandran P, Minnier J, McColgan MD, Alam M, Ellis H, Dunbar DR, Kohnen G, et al. An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease. Nat Med. 2023;29:2939\u201353.","journal-title":"Nat Med"},{"key":"1173_CR46","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1016\/j.cell.2024.05.009","volume":"187","author":"S Sookoian","year":"2024","unstructured":"Sookoian S, Pirola CJ. Resmetirom for treatment of MASH. Cell. 2024;187:2897\u2013e28972891.","journal-title":"Cell"},{"key":"1173_CR47","doi-asserted-by":"publisher","first-page":"109199","DOI":"10.1016\/j.cbi.2020.109199","volume":"330","author":"CY Lian","year":"2020","unstructured":"Lian CY, Zhai ZZ, Li ZF, Wang L. High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms. Chem Biol Interact. 2020;330:109199.","journal-title":"Chem Biol Interact"},{"key":"1173_CR48","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41598-019-57369-9","volume":"10","author":"N Yoshioka","year":"2020","unstructured":"Yoshioka N, Ishigami M, Watanabe Y, Sumi H, Doisaki M, Yamaguchi T, Ito T, Ishizu Y, Kuzuya T, Honda T, et al. Effect of weight change and lifestyle modifications on the development or remission of nonalcoholic fatty liver disease: sex-specific analysis. Sci Rep. 2020;10:481.","journal-title":"Sci Rep"},{"key":"1173_CR49","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","volume":"75","author":"DH Ipsen","year":"2018","unstructured":"Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75:3313\u201327.","journal-title":"Cell Mol Life Sci"},{"key":"1173_CR50","doi-asserted-by":"publisher","first-page":"102401","DOI":"10.1016\/j.jbc.2022.102401","volume":"298","author":"B Yenilmez","year":"2022","unstructured":"Yenilmez B, Kelly M, Zhang GF, Wetoska N, Ilkayeva OR, Min K, Rowland L, DiMarzio C, He W, Raymond N, et al. Paradoxical activation of transcription factor SREBP1c and de novo lipogenesis by hepatocyte-selective ATP-citrate lyase depletion in obese mice. J Biol Chem. 2022;298:102401.","journal-title":"J Biol Chem"},{"key":"1173_CR51","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jhep.2023.10.042","volume":"80","author":"WP Esler","year":"2024","unstructured":"Esler WP, Cohen DE. Pharmacologic inhibition of lipogenesis for the treatment of NAFLD. J Hepatol. 2024;80:362\u201377.","journal-title":"J Hepatol"},{"key":"1173_CR52","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3945\/an.113.004648","volume":"4","author":"DG Mashek","year":"2013","unstructured":"Mashek DG. Hepatic fatty acid trafficking: multiple forks in the road. Adv Nutr. 2013;4:697\u2013710.","journal-title":"Adv Nutr"},{"key":"1173_CR53","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1136\/gut.2010.222844","volume":"60","author":"ME Miquilena-Colina","year":"2011","unstructured":"Miquilena-Colina ME, Lima-Cabello E, S\u00e1nchez-Campos S, Garc\u00eda-Mediavilla MV, Fern\u00e1ndez-Bermejo M, Lozano-Rodr\u00edguez T, Vargas-Castrill\u00f3n J, Buqu\u00e9 X, Ochoa B, Aspichueta P, et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut. 2011;60:1394\u2013402.","journal-title":"Gut"},{"key":"1173_CR54","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.7150\/ijbs.64046","volume":"17","author":"M Qu","year":"2021","unstructured":"Qu M, Zhou X, Wang X, Li H. Lipid-induced S-palmitoylation as a Vital Regulator of Cell Signaling and Disease Development. Int J Biol Sci. 2021;17:4223\u201337.","journal-title":"Int J Biol Sci"},{"key":"1173_CR55","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1039\/D4FO00099D","volume":"15","author":"F Zhang","year":"2024","unstructured":"Zhang F, Fu Y, Wang J, Lang L, Liang S, Zhang S, Wang L, Gao P, Shu G, Zhu C, et al. Conjugated linoleic acid (CLA) reduces intestinal fatty acid uptake and chylomicron formation in HFD-fed mice associated with the inhibition of DHHC7-mediated CD36 palmitoylation and the downstream ERK pathway. Food Funct. 2024;15:5000\u201311.","journal-title":"Food Funct"},{"key":"1173_CR56","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3389\/fphys.2017.00853","volume":"8","author":"Y Liu","year":"2017","unstructured":"Liu Y, Dong W, Shao J, Wang Y, Zhou M, Sun H. Branched-Chain Amino Acid Negatively Regulates KLF15 Expression via PI3K-AKT Pathway. Front Physiol. 2017;8:853.","journal-title":"Front Physiol"},{"key":"1173_CR57","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1016\/j.bbrc.2017.11.187","volume":"495","author":"S Yu","year":"2018","unstructured":"Yu S, Wang F, Tan X, Gao GL, Pan WJ, Luan Y, Ge X. FBW7 targets KLF10 for ubiquitin-dependent degradation. Biochem Biophys Res Commun. 2018;495:2092\u20137.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Nutrition &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12986-026-01173-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12986-026-01173-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12986-026-01173-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:02:27Z","timestamp":1791464547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12986-026-01173-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1173"],"URL":"https:\/\/doi.org\/10.1186\/s12986-026-01173-6","relation":{},"ISSN":["1743-7075"],"issn-type":[{"value":"1743-7075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,12]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research followed the ARRIVE guidelines, and the Animal Ethics Committee of Nanjing Normal University approved all animal experiments [IACUC-20230701].","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"118"}}